These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 26460788)

  • 1. Novel Series of Dihydropyridinone P2X7 Receptor Antagonists.
    Lopez-Tapia F; Walker KA; Brotherton-Pleiss C; Caroon J; Nitzan D; Lowrie L; Gleason S; Zhao SH; Berger J; Cockayne D; Phippard D; Suttmann R; Fitch WL; Bourdet D; Rege P; Huang X; Broadbent S; Dvorak C; Zhu J; Wagner P; Padilla F; Loe B; Jahangir A; Alker A
    J Med Chem; 2015 Nov; 58(21):8413-26. PubMed ID: 26460788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor.
    Swanson DM; Savall BM; Coe KJ; Schoetens F; Koudriakova T; Skaptason J; Wall J; Rech J; Deng X; De Angelis M; Everson A; Lord B; Wang Q; Ao H; Scott B; Sepassi K; Lovenberg TW; Carruthers NI; Bhattacharya A; Letavic MA
    J Med Chem; 2016 Sep; 59(18):8535-48. PubMed ID: 27548392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substituted 5,6-(Dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)-methanones as P2X7 Antagonists.
    Ziff J; Rudolph DA; Stenne B; Koudriakova T; Lord B; Bonaventure P; Lovenberg TW; Carruthers NI; Bhattacharya A; Letavic MA; Shireman BT
    ACS Chem Neurosci; 2016 Apr; 7(4):498-504. PubMed ID: 26754558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationship studies of pyrimidine-2,4-dione derivatives as potent P2X7 receptor antagonists.
    Park JH; Lee GE; Lee SD; Ko H; Kim YC
    Eur J Med Chem; 2015 Dec; 106():180-93. PubMed ID: 26547056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists.
    Rudolph DA; Alcazar J; Ameriks MK; Anton AB; Ao H; Bonaventure P; Carruthers NI; Chrovian CC; De Angelis M; Lord B; Rech JC; Wang Q; Bhattacharya A; Andres JI; Letavic MA
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3157-63. PubMed ID: 26099534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of the P2X7 purinergic receptor in inflammation: an update of antagonists series since 2009 and their promising therapeutic potential.
    Baudelet D; Lipka E; Millet R; Ghinet A
    Curr Med Chem; 2015; 22(6):713-29. PubMed ID: 25515510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P2X7 receptor antagonists for the treatment of systemic inflammatory disorders.
    Gelin CF; Bhattacharya A; Letavic MA
    Prog Med Chem; 2020; 59():63-99. PubMed ID: 32362329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease.
    Bartlett R; Stokes L; Sluyter R
    Pharmacol Rev; 2014 Jul; 66(3):638-75. PubMed ID: 24928329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery, synthesis and SAR of azinyl- and azolylbenzamides antagonists of the P2X₇ receptor.
    Subramanyam C; Duplantier AJ; Dombroski MA; Chang SP; Gabel CA; Whitney-Pickett C; Perregaux DG; Labasi JM; Yoon K; Shepard RM; Fisher M
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5475-9. PubMed ID: 21782426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolution of P2X7 antagonists with a focus on CNS indications.
    Rech JC; Bhattacharya A; Letavic MA; Savall BM
    Bioorg Med Chem Lett; 2016 Aug; 26(16):3838-45. PubMed ID: 27426304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and SAR development of novel P2X7 receptor antagonists for the treatment of pain: part 2.
    Brumfield S; Matasi JJ; Tulshian D; Czarniecki M; Greenlee W; Garlisi C; Qiu H; Devito K; Chen SC; Sun Y; Bertorelli R; Ansell J; Geiss W; Le VD; Martin GS; Vellekoop SA; Haber J; Allard ML
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7287-90. PubMed ID: 22078214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1,4-Naphthoquinones potently inhibiting P2X7 receptor activity.
    Faria RX; Oliveira FH; Salles JP; Oliveira AS; von Ranke NL; Bello ML; Rodrigues CR; Castro HC; Louvis AR; Martins DL; Ferreira VF
    Eur J Med Chem; 2018 Jan; 143():1361-1372. PubMed ID: 29133043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The P2X7 purinergic receptor: An emerging therapeutic target in cardiovascular diseases.
    Chen Z; He L; Li L; Chen L
    Clin Chim Acta; 2018 Apr; 479():196-207. PubMed ID: 29366837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis, and in vitro Evaluation of P2X7 Antagonists.
    T Pournara D; Durner A; Kritsi E; Papakostas A; Zoumpoulakis P; Nicke A; Koufaki M
    ChemMedChem; 2020 Dec; 15(24):2530-2543. PubMed ID: 32964578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tanshinone II A sulfonate, but not tanshinone II A, acts as potent negative allosteric modulator of the human purinergic receptor P2X7.
    Kaiser M; Sobottka H; Fischer W; Schaefer M; Nörenberg W
    J Pharmacol Exp Ther; 2014 Sep; 350(3):531-42. PubMed ID: 24970925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate.
    Letavic MA; Savall BM; Allison BD; Aluisio L; Andres JI; De Angelis M; Ao H; Beauchamp DA; Bonaventure P; Bryant S; Carruthers NI; Ceusters M; Coe KJ; Dvorak CA; Fraser IC; Gelin CF; Koudriakova T; Liang J; Lord B; Lovenberg TW; Otieno MA; Schoetens F; Swanson DM; Wang Q; Wickenden AD; Bhattacharya A
    J Med Chem; 2017 Jun; 60(11):4559-4572. PubMed ID: 28493698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel purine-based heterocyclic P2X7 receptor antagonists.
    Kwak SH; Lee WG; Lee YJ; Lee SD; Kim YC; Ko H
    Bioorg Chem; 2015 Aug; 61():58-65. PubMed ID: 26123174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of P2X7 receptor on inflammatory diseases and its mechanism].
    Xu H; Liang SD
    Sheng Li Xue Bao; 2013 Apr; 65(2):244-52. PubMed ID: 23598883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P2X7 receptor: an emerging target in central nervous system diseases.
    Sperlágh B; Illes P
    Trends Pharmacol Sci; 2014 Oct; 35(10):537-47. PubMed ID: 25223574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of P2X7 receptors in tissue fibrosis: a brief review.
    Gentile D; Natale M; Lazzerini PE; Capecchi PL; Laghi-Pasini F
    Purinergic Signal; 2015 Dec; 11(4):435-40. PubMed ID: 26318434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.